E-Mail
PHILADELPHIA, PA - The first National Institutes of Health (NIH) National Cancer Institute (NCI)-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases. These results were recently published in
JAMA Oncology.
The results of the Phase I NRG-BR001 trial, conducted by the NCI National Clinical Trials Network group NRG Oncology, indicate that SBRT treatment in standard doses was safe for 35 evaluable patients with a median of 3 metastases. There were no dose-limiting toxicities and over 50% of trial participants were alive at 2 years following treatment.
ACR Launches National Clinical Imaging Research Registry
The registry is a powerful platform for analytic tools and distributed data
Getty Images
April 21, 2021 The American College of Radiology (ACR) has brought together the full power of its world-class informatics and clinical research resources to launch the innovative ACR National Clinical Imaging Research Registry (ANCIRR). The six current and eight planned ANCIRR registries can collect and curate images and diverse clinical data from multiple practice settings to produce large data sets that enable researchers to address complex scientific questions and produce results applicable across various care settings, geographic locations and multiple populations.
Projects & Studies
Description
The Acute Effects of Exercise on Breast Cancer Biomarkers (ACE Study) is enrolling women to test the effect of moderate intensity exercise on cancer risk factors such as biomarkers in healthy women. Knowing if exercise significantly alters these biomarkers, could help support guidelines for daily exercise for breast cancer prevention and could indicate that exercise even without weight loss is beneficial.
Advanced Colorectal Cancer of Serrated Subtype (ACCESS) Study
Description
Funding Agency: National Institutes of Health
Advancing our Understanding of the Etiologies and Mutational Landscapes of Basal-like, Luminal A, and Luminal B Breast Cancer
Description
Addressing research gaps in the molecular subtypes of breast cancer, we are taking a multidisciplinary approach to study the epidemiology and mutational landscapes of basal-like, luminal A, and luminal B tumors.
Commemorating the Contributions of Cancer Research Greats
March 12, 2021, by Norman E. Sharpless, M.D.
Dr. Emil Freireich, who died in February 2021, working with a blood cell separator at MD Anderson Cancer Center.
Credit: National Cancer Institute
There are those moments, those events that make it the ideal time to stop and reflect on the past.
Such is the case with the passing of Dr. Emil Freireich, who died last month at the age of 93 in Houston, his long-time home. Having begun his career in the 1950s at NCI, Dr. Freireich went on to become one of the most accomplished physician–scientists to ever step into a lab or comfort a worried patient.
NIDA has selected postdoctoral researchers from Germany and Thailand to receive INVEST Drug Abuse Research Fellowships:
Laura Brandt, Ph.D. (Germany), will work with Edward Nunes, M.D., as an INVEST/Clinical Trials Network (CTN) fellow at Columbia University Irving Medical Center and the New York State Psychiatric Institute. Dr. Brandt just completed an Erwin Schrödinger Fellowship supported by the Austrian Science Fund, where she was the principal investigator on a project that evaluated fidelity and implementation of programs to prevent opioid overdose and distribute Naloxone to opioid users. She has also conducted research on violent experiences among females diagnosed with gambling disorder. During her fellowship, Dr. Brandt plans to identify and validate surrogate endpoints for long-term opioid use disorder (OUD) treatment outcomes using an aggregate data set of four large, multisite, pragmatic CTN trials that have tested all three FDA-approved medications to treat OUD as well